Meropenem Bausch Health (Meropenem Anhydrous)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins. This blocks the cross‑linking of peptidoglycan strands, weakening the wall and causing osmotic lysis of the bacteria. Its stability against most β‑lactamases gives it a broad spectrum of activity.

The dosage of Meropenem Bausch Health is determined by the prescribing clinician based on infection severity, patient weight, renal function, and local susceptibility patterns. The product is supplied as an injectable solution for intravenous administration, and the exact regimen should follow the prescriber’s order.

The pregnancy safety category for meropenem is not definitively established. It should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; caution is advised and a risk‑benefit assessment should be performed by the healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain where required) and assist with import documentation.

Meropenem shares the broad‑spectrum activity of other carbapenems such as imipenem and ertapenem but differs in its stability against certain β‑lactamases and its dosing frequency. It is often preferred for infections caused by multidrug‑resistant Gram‑negative organisms and for patients with a higher risk of seizures, where imipenem may be less suitable.

Meropenem Bausch Health should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it appears discolored or if the storage conditions have been compromised.

The product is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional, typically over a 15‑30 minute infusion period, according to the prescriber’s instructions. Infusion rates may be adjusted based on patient tolerance and renal function.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, Clostridioides difficile‑associated colitis, severe allergic reactions such as anaphylaxis, and significant neutropenia. Clinicians should monitor patients closely for neurological changes, gastrointestinal symptoms and signs of hypersensitivity.

Meropenem should be avoided in patients with a known hypersensitivity to carbapenems or other β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment without dose adjustment, or those receiving concomitant valproic acid, unless the benefits outweigh the risks.